Statins for the Primary Prevention of XXXX in the Elderly.

@entity1 @entity65 @entity301
OBJECTIVE: The objective is to review the evidence evaluating the efficacy of statin therapy for primary prevention of @entity65 in the elderly. Data Sources: A literature search of MEDLINE and PubMed (1966-January 2013) using the terms HMG-CoA reductase inhibitor, statin, primary prevention, elderly, and geriatrics was performed. The search was limited to clinical trials, meta-analyses, and subanalyses, including primary prevention @entity1 . Bibliographies of selected articles were examined to identify additional clinical trials. Study Selection: Fourteen clinical trials, subanalyses, and meta-analyses were reviewed. A total of seven clinical trials and subanalyses evaluating statin therapy versus placebo in the elderly primary prevention @entity1 with a primary endpoint of hard @entity301 were included. DATA EXTRACTION: Data collected from the clinical trials and subanalyses included number of elderly @entity1 randomized, therapy, duration of follow-up, and the incidence of coronary events. DATA SYNTHESIS: The average annual rates of first CV event increases as @entity1 age. There is strong evidence that supports the use of statins for secondary prevention; although primary prevention, specifically in the elderly, is less defined. This paper reviews the literature specifically for primary prevention, for which the results have shown a trend toward decreased first occurrence of @entity301 with statin therapy in elderly @entity1 . CONCLUSION: Statin therapy should be considered as a primary prevention therapy against @entity301 for elderly @entity1 . Evidence-based clinical benefits are seen in this @entity1 population. However, clinical judgment and consideration of comorbidities that may impact life expectancy should be assessed to determine appropriateness for individual @entity1 .
